Format

Send to

Choose Destination
Graefes Arch Clin Exp Ophthalmol. 2016 Dec;254(12):2327-2332. Epub 2016 Jun 11.

Intravitreal aflibercept for myopic choroidal neovascularization.

Author information

1
Unità Operativa di Oftalmologia, Ospedale di Melegnano, Via Pandina 1, 20077, Melegnano, (MI), Italy. pece.retina@mclink.it.
2
Fondazione Retina 3000, Milan, Italy.

Abstract

PURPOSE:

To assess the use of aflibercept for the treatment of subfoveal myopic choroidal neovascularization (CNV).

METHODS:

Thirty-two patients (33 eyes) with myopic subfoveal CNV were consecutively enrolled in this prospective open-label case series. All patients were treated with an off-label 2-mg intravitreal injection of aflibercept. After the first injection, administration of aflibercept followed an "on demand" pro re nata (PRN) regimen. The primary outcome was change in best-corrected visual acuity (BCVA) score after 12 months.

RESULTS:

Mean follow-up was 12 months, and the median number of aflibercept injections was 2.0 (range 1-4). Overall, mean BCVA improved from 0.59 ± 0.37 logMAR at baseline to 0.38 ± 0.33 logMAR at 12 months, a change of -0.21 ± 0.23 logMAR (p < 0.0001), and from 70.5 ± 18.5 to 81.1 ± 16.4 letters, a change of 10.6 ± 11.4 (p < 0.0001). Improvements were similar among patients irrespective of previous PDT. The Increase in BCVA was greater in younger patients (aged < 50 years) and those with baseline BCVA of ≤ 75 letters.

CONCLUSION:

Intravitreal aflibercept in a PRN regimen is effective for the treatment of myopic CNV, with no apparent short-term safety effects. Treated eyes had BCVA gains after 12 months, with a median of two injections.

KEYWORDS:

Aflibercept; Anti-VEGF therapy; Choroidal neovascularization; Pathological myopia

PMID:
27286893
DOI:
10.1007/s00417-016-3396-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center